Aptahem receives patent protection in Israel for patent family 2
Aptahem AB (publ) announces today that the company has received patent protection in Israel for patent family 2 from the Israeli Patent Office.With the approval in Israel of patent application 273759, the protection of the company’s drug candidate Apta-1 within patent family 2 in Israel, Israeli Patent No. 273759, is valid until the end of 2038. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the
